Eloxx Pharmaceuticals Inc (ELOX)

[Camaro1093]

Senesco Technologies Receives Notice of Non Compliance From NYSE Amex

NEW BRUNSWICK, N.J., April 8, 2010 /PRNewswire via COMTEX/ -- Senesco
Technologies, Inc. (the "Company") (SNT) has received a notice from the NYSE Amex
LLC ("NYSE") providing notification that the Company does not meet one of the
NYSE's continued listing standards as set forth in Part 10 of the NYSE company
guide and the Company has therefore become subject to the procedures and
requirements of Section 1009 of the NYSE company guide. Specifically, the Company
is not in compliance with Section 704 of the NYSE company guide in that it failed
to hold an annual meeting of its stockholders during the year ended December 31,
2010.

To maintain an NYSE listing, Senesco must submit a plan by April 15, 2010
advising the NYSE of action it has taken, or will take, that would bring Senesco
into compliance with the continued listing standards by July 1, 2010. The Company
is taking steps to prepare and submit such a plan to the NYSE on or before April
15, 2010.

As previously disclosed, the Company recently executed a financing and must seek
stockholder approval of certain aspects of the financing. Therefore, the Company
anticipates that it will simultaneously hold its annual meeting at the same time
it holds a meeting to seek stockholder approval of certain aspects of the
financing. The Company expects to file a proxy statement, which will include the
information on its annual meeting, in the near future.

The Listings Qualifications Department of the NYSE will evaluate Senesco's plan
and determine whether it reasonably demonstrates the Company's ability to regain
compliance with the continued listing standards by July 1, 2010. If the NYSE
accepts Senesco's plan, the Company may be able to continue its listing during
the plan period, provided that Senesco demonstrates progress consistent with its
plan and complies with other applicable NYSE listing qualifications. If the
Company fails to submit a satisfactory plan or fails to demonstrate progress
consistent with the plan accepted by the NYSE, the NYSE may initiate delisting
procedures. During the plan period, Senesco will be subject to periodic review to
determine whether it is achieving progress consistent with the plan.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New
Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay
cell death in mammals (apoptosis) to determine if the technology is applicable in
human medicine. Accelerating apoptosis may have applications to development of
cancer treatments. Delaying apoptosis may have applications to certain
inflammatory and ischemic diseases. Senesco takes its name from the scientific
term for the aging of plant cells: senescence. Delaying cell breakdown in plants
extends freshness after harvesting, while increasing crop yields, plant size and
resistance to environmental stress. The Company believes that its technology can
be used to develop superior strains of crops without any modification other than
delaying natural plant senescence. Senesco has partnered with leading-edge
companies engaged in agricultural biotechnology and earns research and
development fees for applying its gene-regulating platform technology to enhance
its partners' products.

Certain statements included in this press release are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results could differ materially from such statements expressed or implied
herein as a result of a variety of factors, including, but not limited to: the
ability of the Company to consummate additional financings; the development of
the Company's gene technology; the approval of the Company's patent applications;
the successful implementation of the Company's research and development programs
and joint ventures; the success of the Company's license agreements; the
acceptance by the market of the Company's products; success of the Company's
preliminary studies and preclinical research; competition and the timing of
projects and trends in future operating performance, the Company's ability to
comply with the continued listing standards of the AMEX, as well as other factors
expressed from time to time in the Company's periodic filings with the Securities
and Exchange Commission (the "SEC"). As a result, this press release should be
read in conjunction with the Company's periodic filings with the SEC. The
forward-looking statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.



Company Contact:Investor Relations Contact:
-------------------------------------------
Senesco Technologies, Inc.FD
Jack Van HulstBrian Ritchie
Chief Executive Officer([e-mail])
([e-mail])[phone]
[phone]





SOURCE Senesco Technologies, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved